Fig. 7: Protective efficacy of mAb 5F8 in a neonatal mouse model of ZIKV infection. | Cell Discovery

Fig. 7: Protective efficacy of mAb 5F8 in a neonatal mouse model of ZIKV infection.

From: A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein

Fig. 7

Groups of one-day-old suckling ICR mice (n = 11–12/group) were inoculated i.p. with PBS, 10 µg/g of 5F8, 50 µg/g of 5F8, or 50 µg/g of control mAb D5, respectively, followed 24 hours later by i.p. injection with the mouse-adapted ZIKV strain ZIKV/MAV-HQ. (a) Survival and (b) clinical score were then monitored daily for 21 days following challenge. Clinical scores were graded as follows: 0, healthy; 1, reduced mobility; 2, limb weakness or toe walking; 3, tremors or imbalance; 4, paralysis; 5, moribund or death. c, d Representative mice treated with control mAb D5 (c) or anti-ZIKV mAb 5F8 (d) at 12 days post-infection. The black arrow indicates limb paralysis. Statistical significance was indicated as follows: n.s., no significant difference (P ≥ 0.05); **P < 0.01.

Back to article page